[July 09, 2014] |
 |
Research and Markets: Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/z6pd5l/frontier_pharma)
has announced the addition of the "Frontier
Pharma: Psoriasis - Identifying and Commercializing First-in-Class
Innovation" report to their offering.
Over the last decade, a greater understanding of the underlying
pathophysiology of psoriasis has increased emphasis on developing
immuneomodulating therapies, as opposed to largely symptomatic
treatments. This is currently reflected in a competitive market
dominated by multiple disease-modifying biologic therapies (inhibitors
of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite
this, there are significant unmet needs in the market, including afety
concerns regarding immunomodulation. This is a particularly important
issue for the long-term commercial and clinical success of psoriatic
therapeutics, especially for emerging biologics. Another unmet need is
ease of drug application, as biologic drug delivery is invasive and
painful.
Scope:
-
A brief introduction to psoriasis, including symptoms,
pathophysiology, and overview of pharmacotherapy
-
The changing molecular target landscape between market and pipeline
and particular focal points of innovation
-
Overview of how innovative products are contributing to the pipeline
and market for psoriasis
-
Comprehensive review of the pipeline for first-in-class therapies,
analyzed on the basis of phase distribution, molecule type, molecular
target, and administration route
-
Identification and assessment of first-in-class molecular targets with
a particular focus on early-stage programs of which clinical utility
has yet to be evaluated, as well as literature reviews on novel
molecular targets
-
Assessment of the licensing and co-development deals for psoriasis
therapies
Key Topics Covered:
1 Table of Contents
2 The Case for Innovation
3 Clinical and Commercial Landscape
4 Assessment of Psoriasis Pipeline and Innovation
5 First-in-Class Target (News - Alert) and Pipeline Program Evaluation
6 Deals and Strategic Consolidations
7 Appendix
For more information visit http://www.researchandmarkets.com/research/z6pd5l/frontier_pharma

[ Back To TMCnet.com's Homepage ]
|